Asset Details
Do you wish to reserve the book?
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects
Do you wish to request the book?
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects
2010
Overview
Purpose
To investigate the potential effect of tolterodine on the human heart rate variability (HRV). Oral antimuscarinic treatment for overactive bladder might significantly alter HRV, which is an important predictor for cardiac and all-cause mortality. Yet, little information exists regarding the influence of oral antimuscarinics on the HRV.
Methods
Healthy female volunteers were randomly assigned to either placebo, tolterodine extended release (ER) 4 or 8 mg. Before and 4 h post treatment, a 10 min electrocardiogram (ECG) was recorded in supine position. Frequency domain and time domain analysis of both ECG measurements resulted in very low frequency (VLF), low frequency (LF), and high frequency (HF) data, the root mean square of differences of successive NN (= normal to normal, i.e. interval between two R-peaks) intervals (RMSSD), and the standard deviation of the NN intervals (SDNN).
Results
Thirty subjects (mean age: 23.7 ± 2.3 years) were investigated. Placebo caused no significant HRV changes. Tolterodine 4 mg significantly increased heart rate (HR) and significantly decreased VLF. Tolterodine 8 mg significantly decreased HF, VLF, RMSSD and SDNN and significantly increased HR and LF/HF ratio. The changes observed with 4 mg were not significantly different versus placebo, but 8 mg significantly increased LF/HF as compared to placebo.
Conclusions
A single dose of 8 mg tolterodine ER, but not 4 mg seems to reduce resting HRV versus placebo in young healthy subjects. This might be particular relevant for patients with pre-existing cardiac conditions on daily overactive bladder drug treatment and should be further investigated in larger trials.
Publisher
Springer-Verlag,Springer,Springer Nature B.V
Subject
/ Adult
/ Benzhydryl Compounds - administration & dosage
/ Benzhydryl Compounds - pharmacology
/ Benzhydryl Compounds - therapeutic use
/ Biological and medical sciences
/ Cresols - administration & dosage
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Medicine
/ Muscarinic Antagonists - administration & dosage
/ Muscarinic Antagonists - pharmacology
/ Muscarinic Antagonists - therapeutic use
/ Nephrology. Urinary tract diseases
/ Oncology
/ Phenylpropanolamine - administration & dosage
/ Phenylpropanolamine - pharmacology
/ Phenylpropanolamine - therapeutic use
/ Urinary Bladder, Overactive - drug therapy
/ Urinary system involvement in other diseases. Miscellaneous
/ Urinary tract. Prostate gland
/ Urology
